Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms

Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplasms ranging from well-differentiated, slowly growing tumors to poorly differentiated carcinomas. These tumors are generally characterized by indolent course and quite often absence of specific symptoms, thus eluding diagnosis until at an advanced stage. This underscores the importance of establishing a prompt and accurate diagnosis. The gold-standard remains histopathology. This should contain neuroendocrine-specific markers, such as chromogranin A; and also, an estimate of the proliferation by Ki-67 (or MIB-1), which is pivotal for treatment selection and prognostication. Initial work-up involves assessment of serum Chromogranin A and in selected patients gut peptide hormones. More recently, the measurement of multiple NEN-related transcripts, or the detection of circulating tumor cells enhanced our current diagnostic armamentarium and appears to supersede historical serum markers, such as Chromogranin A. Standard imaging procedures include cross-sectional imaging, either computed tomography or magnetic resonance, and are combined with somatostatin receptor scintigraphy. In particular, the advent of 111In-DTPA-octreotide and more recently PET/CT and 68Ga-DOTA-Octreotate scans revolutionized the diagnostic landscape of NENs. Likewise, FDG PET represents an invaluable asset in the management of high-grade neuroendocrine carcinomas. Lastly, endoscopy, either conventional, or more advanced modalities such as endoscopic ultrasound, capsule endoscopy and enteroscopy, are essential for the diagnosis and staging of gastroenteropancreatic neuroendocrine neoplasms and are routinely integrated in clinical practice. The complexity and variability of NENs necessitate the deep understanding of the current diagnostic strategies, which in turn assists in offering optimal patient-tailored treatment. The current review article presents the diagnostic work-up of GEP-NENs and all the recent advances in the field.

[1]  C. Fiorino,et al.  Prediction of the characteristics of aggressiveness of pancreatic neuroendocrine neoplasms (PanNENs) based on CT radiomic features , 2022, European Radiology.

[2]  D. Bailey,et al.  Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score , 2022, British Journal of Cancer.

[3]  S. Busoni,et al.  Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade , 2022, La radiologia medica.

[4]  N. Suzuki,et al.  State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors , 2022, Current Treatment Options in Oncology.

[5]  V. Prasad,et al.  European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease , 2022, Journal of neuroendocrinology.

[6]  M. Papotti,et al.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms , 2022, Endocrine Pathology.

[7]  M. Caplin,et al.  The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors , 2022, Clinical nuclear medicine.

[8]  Clara C. Chen,et al.  Parathyroid Imaging: Past, Present, and Future , 2022, Frontiers in Endocrinology.

[9]  M. Weickert,et al.  The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours , 2021, Frontiers in Endocrinology.

[10]  G. Cassese,et al.  Diagnosis and Management of Rectal Neuroendocrine Tumors (NETs) , 2021, Diagnostics.

[11]  D. Metz,et al.  Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors , 2021, JAMA network open.

[12]  Tsuyoshi Hayashi,et al.  Role of Endoscopic Ultrasound in the Diagnosis of Pancreatic Neuroendocrine Neoplasms , 2020, Diagnostics.

[13]  A. Koffas,et al.  Managing carcinoid heart disease in patients with neuroendocrine tumours. , 2020, Annales d'endocrinologie.

[14]  Mohid S. Khan,et al.  Prognostic threshold for circulating tumour cells in patients with pancreatic and midgut neuroendocrine tumours. , 2020, The Journal of clinical endocrinology and metabolism.

[15]  D. Cuthbertson,et al.  The impact of lymph node metastases and right hemicolectomy on outcomes in appendiceal neuroendocrine tumours (aNETs). , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  K. Öberg Molecular Genomic Blood Biomarkers for Neuroendocrine Tumors: The Long and Winding Road from Berzelius and Bence Jones to a Neuroendocrine Destination , 2020, Neuroendocrinology.

[17]  M. Falconi,et al.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Califano,et al.  A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Jeffrey E. Lee,et al.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors , 2020, Pancreas.

[20]  G. Kaltsas,et al.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms , 2020, Endocrine reviews.

[21]  S. Severi,et al.  PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  L. Eusebi,et al.  Endoscopic ultrasound-guided fine-needle aspiration vs fine-needle biopsy for the diagnosis of pancreatic neuroendocrine tumors , 2019, Endoscopy International Open.

[23]  I. Modlin,et al.  An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis , 2019, Neuroendocrinology.

[24]  G. Vitale,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Precision medicine in neuroendocrine neoplasms: an update on current management and future perspectives. , 2019, European journal of endocrinology.

[25]  L. Hofland,et al.  Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives , 2018, Drugs.

[26]  I. Drozdov,et al.  The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. , 2018, Endocrinology and metabolism clinics of North America.

[27]  R. Jensen,et al.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies , 2018, Expert review of anticancer therapy.

[28]  A. Kambadakone,et al.  MR Imaging of Pancreatic Neuroendocrine Tumors. , 2018, Magnetic resonance imaging clinics of North America.

[29]  A. Cooperman,et al.  Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat? , 2018, The Surgical clinics of North America.

[30]  S. Lo,et al.  The role of pre‐operative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary? , 2018, Journal of surgical oncology.

[31]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[32]  A. Gangi,et al.  Multifocality in Small Bowel Neuroendocrine Tumors , 2018, Journal of Gastrointestinal Surgery.

[33]  N. Kumta,et al.  Diagnosis and Management of Rectal Neuroendocrine Tumors , 2017, Clinical endoscopy.

[34]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[35]  R. Hruban,et al.  Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification , 2017, AJSP: Reviews and Reports.

[36]  E. Nakakura,et al.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society , 2017, Pancreas.

[37]  R. Lloyd,et al.  WHO classification of tumours of endocrine organs , 2017 .

[38]  V. Mazzaferro,et al.  The role of wireless capsule endoscopy (WCE) in the detection of occult primary neuroendocrine tumors. , 2017, Journal of gastrointestinal and liver diseases : JGLD.

[39]  V. Ostojić,et al.  Incidence of diabetic ketosis and ketoacidosis in Caucasian adults with type 2 diabetes mellitus: a population-based study , 2017 .

[40]  R. Jensen,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers , 2017, Neuroendocrinology.

[41]  S. Fanti,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging , 2017, Neuroendocrinology.

[42]  S. Kim,et al.  Is endoscopic ultrasonography essential for endoscopic resection of small rectal neuroendocrine tumors? , 2017, World journal of gastroenterology.

[43]  R. Jensen,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification , 2017, Neuroendocrinology.

[44]  M. Pavel,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors , 2017, Neuroendocrinology.

[45]  S. Michopoulou,et al.  Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors , 2017, The Journal of Nuclear Medicine.

[46]  Denis A. Cortese,et al.  A Five-Year Experience , 2017 .

[47]  G. Vitale,et al.  Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors , 2017, Endocrine.

[48]  Laura H. Tang,et al.  A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas , 2016, The American journal of surgical pathology.

[49]  A. Dohan,et al.  Neuroendocrine tumors of the small bowel: evaluation with MR-enterography. , 2016, Clinical imaging.

[50]  A. Larghi,et al.  Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography , 2016, Pancreas.

[51]  Raju Sharma,et al.  Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma. , 2016, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[52]  Y. Oda,et al.  Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors , 2016, Scandinavian journal of gastroenterology.

[53]  E. Krenning,et al.  ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum , 2016, Neuroendocrinology.

[54]  R. Kianmanesh,et al.  ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update , 2016, Neuroendocrinology.

[55]  R. Jensen,et al.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.

[56]  R. Main Long-term Evaluation , 2016 .

[57]  C. Rottenburger,et al.  Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. , 2016, Best practice & research. Clinical endocrinology & metabolism.

[58]  K. Nackaerts,et al.  Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours , 2016, European Radiology.

[59]  I. Modlin,et al.  Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. , 2015, The Journal of clinical endocrinology and metabolism.

[60]  J. Mortensen,et al.  64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients , 2015, The Journal of Nuclear Medicine.

[61]  K. Delman,et al.  Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach , 2015, Annals of Surgical Oncology.

[62]  M. Ruiz,et al.  Contribution of 111In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours , 2015, Nuclear medicine communications.

[63]  U. Knigge,et al.  PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. , 2014, Future oncology.

[64]  I. Adalet,et al.  Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors? , 2014, The Journal of Nuclear Medicine.

[65]  M. Cuggia,et al.  High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation , 2014, The Journal of Nuclear Medicine.

[66]  G. Corradi,et al.  68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial , 2014, The Journal of Nuclear Medicine.

[67]  M. Büchler,et al.  A Systematic Review of Localization, Surgical Treatment Options, and Outcome of Insulinoma , 2014, Pancreas.

[68]  A. Faggiano,et al.  Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. , 2014, Endocrine-related cancer.

[69]  B. Ge,et al.  Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis , 2014, Acta radiologica.

[70]  G. Rindi,et al.  The 2010 WHO Classification of Digestive Neuroendocrine Neoplasms: a Critical Appraisal four years after Its Introduction , 2014, Endocrine Pathology.

[71]  G. Antoni,et al.  Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. , 2014, The Journal of clinical endocrinology and metabolism.

[72]  A. Larghi,et al.  Grading of EUS-FNA cytologic specimens from patients with pancreatic neuroendocrine neoplasms: it is time move to tissue core biopsy? , 2014, Gland surgery.

[73]  T. Ohtsuka,et al.  Expression of Glucagon-Like Peptide 1 Receptor and its Effects on Biologic Behavior in Pancreatic Neuroendocrine Tumors , 2014, Pancreas.

[74]  C. Sempoux,et al.  Pancreatic neuroendocrine tumour grading on endoscopic ultrasound‐guided fine needle aspiration: high reproducibility and inter‐observer agreement of the Ki‐67 labelling index , 2013, Cytopathology : official journal of the British Society for Clinical Cytology.

[75]  A. Scarpa,et al.  Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. , 2014, Surgery.

[76]  J. Bomanji,et al.  Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors. , 2014, PET clinics.

[77]  Xubao Liu,et al.  Is laparoscopic approach for pancreatic insulinomas safe? Results of a systematic review and meta-analysis. , 2014, The Journal of surgical research.

[78]  C. Stanley,et al.  The surgical management of insulinomas in children. , 2013, Journal of pediatric surgery.

[79]  Yulian Wu,et al.  Surgical treatment of pancreatic islet cell tumor: report of 44 cases. , 2013, Hepato-gastroenterology.

[80]  A. Bellizzi Assigning Site of Origin in Metastatic Neuroendocrine Neoplasms: A Clinically Significant Application of Diagnostic Immunohistochemistry , 2013, Advances in anatomic pathology.

[81]  F. Tubach,et al.  High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. , 2013, Radiology.

[82]  L. Breimer,et al.  Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[83]  L. Mishra,et al.  Technologies for deriving primary tumor cells for use in personalized cancer therapy. , 2013, Trends in biotechnology.

[84]  R. Jensen,et al.  Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1: A Prospective Study , 2013, Medicine.

[85]  Mohid S. Khan,et al.  Circulating tumor cells as prognostic markers in neuroendocrine tumors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  H. Sorbye,et al.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  Y. Menda,et al.  The Value of Preoperative Imaging in Small Bowel Neuroendocrine Tumors , 2013, Annals of Surgical Oncology.

[88]  U. Knigge,et al.  Surgery for GEP-NETs. , 2012, Best practice & research. Clinical gastroenterology.

[89]  M. Falconi,et al.  Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. , 2012, Gastrointestinal endoscopy.

[90]  A. Miyauchi,et al.  Delay in the diagnosis of multiple endocrine neoplasia type 1: typical symptoms are frequently overlooked. , 2012, Endocrine journal.

[91]  A. Scarpa,et al.  TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. , 2012, Journal of the National Cancer Institute.

[92]  I. Shimon,et al.  The Role of Cell Lines in the Study of Neuroendocrine Tumors , 2012, Neuroendocrinology.

[93]  P. Castaldi,et al.  Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis , 2012, Endocrine.

[94]  P. Ameri,et al.  Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What’s New? , 2012, Neuroendocrinology.

[95]  H. Sasano,et al.  ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms , 2011, Neuroendocrinology.

[96]  M. Papotti,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Colorectal Neuroendocrine Neoplasms , 2011, Neuroendocrinology.

[97]  T. Gress,et al.  ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas , 2011, Neuroendocrinology.

[98]  R. Jensen,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes , 2011, Neuroendocrinology.

[99]  P. Cumming,et al.  Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.

[100]  H. Amthauer,et al.  68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol , 2011, The Journal of Nuclear Medicine.

[101]  M. Caplin,et al.  Risk factors for the development and progression of carcinoid heart disease. , 2011, The American journal of cardiology.

[102]  J. Tokar,et al.  Small Bowel Cancers Diagnosed by Device-Assisted Enteroscopy at a U.S. Referral Center: A Five-Year Experience , 2011, Digestive Diseases and Sciences.

[103]  Ben Lawrence,et al.  The epidemiology of gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.

[104]  Mohid S. Khan,et al.  Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors , 2011, Clinical Cancer Research.

[105]  D. Breen,et al.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) , 2005, Gut.

[106]  A. Goules,et al.  Prognostic Factors and Survival , 2011 .

[107]  P. Rajiah,et al.  Computed tomography of cardiac and pericardiac masses. , 2011, Journal of cardiovascular computed tomography.

[108]  P. Veit-Haibach,et al.  Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component , 2011, European Radiology.

[109]  A. Bockisch,et al.  The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors , 2010, Annals of surgery.

[110]  D. Visvikis,et al.  Distribution pattern of 68Ga-DOTATATE in disease-free patients , 2010, Nuclear medicine communications.

[111]  Zhi-gang Yang,et al.  Accuracy and reproducibility of assessing right ventricular function with 64-section multi-detector row CT: comparison with magnetic resonance imaging. , 2010, International journal of cardiology.

[112]  A. Hackshaw,et al.  Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours , 2010, British Journal of Cancer.

[113]  F. Pilleul,et al.  Value of CT enteroclysis in suspected small-bowel carcinoid tumors. , 2010, AJR. American journal of roentgenology.

[114]  Ka Kit Wong,et al.  Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. , 2010, Academic radiology.

[115]  E. Nakakura,et al.  Identification of Unknown Primary Tumors in Patients With Neuroendocrine Liver Metastases , 2010, Archives of surgery.

[116]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[117]  三井 啓吾,et al.  Role of double-balloon endoscopy in the diagnosis of small-bowel tumors : the first Japanese multicenter study , 2010 .

[118]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[119]  F. Forrer,et al.  Glucagon-like peptide-1 receptor imaging for localization of insulinomas. , 2009, The Journal of clinical endocrinology and metabolism.

[120]  Shinji Tanaka,et al.  Role of double-balloon endoscopy in the diagnosis of small-bowel tumors: the first Japanese multicenter study. , 2009, Gastrointestinal endoscopy.

[121]  R. Bale,et al.  Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009, Journal of Nuclear Medicine.

[122]  P. Cryer,et al.  Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. , 2009, The Journal of clinical endocrinology and metabolism.

[123]  M. Vatn,et al.  Small intestinal neuroendocrine tumors: Prognostic factors and survival , 2009, Scandinavian journal of gastroenterology.

[124]  A. Groves,et al.  A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors , 2008, Journal of Nuclear Medicine.

[125]  R. Bale,et al.  Tyr 3 -Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009 .

[126]  P. Malfertheiner,et al.  Detection of Neuroendocrine Tumors of the Small Bowel by Double Balloon Enteroscopy , 2009, Digestive Diseases and Sciences.

[127]  M. Caplin,et al.  Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. , 2008, The American journal of cardiology.

[128]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[129]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  P. Erba,et al.  Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[131]  F. Schmidt Meta-Analysis , 2008 .

[132]  A. Scarpa,et al.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.

[133]  F. D. De Braud,et al.  Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. , 2007, Endocrine-related cancer.

[134]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[135]  C. Nanni,et al.  68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[136]  J. Manson,et al.  Prospective Study of , 2007 .

[137]  J. Saurin,et al.  Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. , 2006, Radiology.

[138]  R. Jensen,et al.  Serum Gastrin in Zollinger-Ellison Syndrome: I. Prospective Study of Fasting Serum Gastrin in 309 Patients From the National Institutes of Health and Comparison With 2229 Cases From the Literature , 2006, Medicine.

[139]  E. D. de Vries,et al.  Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. , 2006, The Lancet. Oncology.

[140]  A. Hubalewska-Dydejczyk,et al.  99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[141]  Joel G Fletcher,et al.  CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[142]  H. Lochs,et al.  The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. , 2006, Gastrointestinal endoscopy.

[143]  B. Weinhold Epigenetics: The Science of Change , 2006, Virchows Archiv.

[144]  R. Jensen,et al.  Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. , 2005, Best practice & research. Clinical gastroenterology.

[145]  D. Holdstock Past, present--and future? , 2005, Medicine, conflict, and survival.

[146]  T. de Baère,et al.  Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  A. Ferrari,et al.  EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery. , 2004, Gastrointestinal endoscopy.

[148]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[149]  R. Wahl,et al.  Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS , 2004, Abdominal Imaging.

[150]  H. Gouya,et al.  CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. , 2003, AJR. American journal of roentgenology.

[151]  J. Fletcher,et al.  Preoperative detection of pancreatic insulinomas on multiphasic helical CT. , 2003, AJR. American journal of roentgenology.

[152]  J. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.

[153]  Uwe Haberkorn,et al.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[154]  R. Lloyd Practical markers used in the diagnosis of neuroendocrine tumors , 2003, Endocrine pathology.

[155]  S. Gabriel,et al.  Systematic Review of the Literature , 2021, Adherence to Antiretroviral Therapy among Perinatal Women in Guyana.

[156]  G. delle Fave,et al.  Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid , 2001, European journal of gastroenterology & hepatology.

[157]  J. Norton,et al.  Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-6. , 2001, Archives of surgery.

[158]  D. Jonkers,et al.  Serum chromogranin A as a screening test for gastric enterochromaffin‐like cell hyperplasia during acid‐suppressive therapy , 2001, European journal of clinical investigation.

[159]  M. Falconi,et al.  Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization , 2001, European Radiology.

[160]  E. D. de Vries,et al.  Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. , 2000, Clinical chemistry.

[161]  Michelle A. Anderson,et al.  Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas , 2000, American Journal of Gastroenterology.

[162]  T. Ichikawa,et al.  Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. , 2000, Radiology.

[163]  B. Wiedenmann,et al.  Endoscopic Ultrasonography of Neuroendocrine Tumours , 2000, Digestion.

[164]  C. Angelis,et al.  Endosonography in decision making and management of gastrointestinal endocrine tumors. , 1999, European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology.

[165]  J. Doppman,et al.  Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  T. Ichikawa,et al.  Neuroendocrine Tumor of the Pancreas : Biphasic CT versus MR Imaging in Tumor Detection , 1999 .

[167]  D. Huglo,et al.  Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. , 1998, Surgery.

[168]  S. Fanti,et al.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours , 1998, European Journal of Nuclear Medicine.

[169]  J. Mcnamara,et al.  Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. , 1998, American journal of surgery.

[170]  L. Holmberg,et al.  Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[171]  H. Buhr,et al.  Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. , 1996, Gut.

[172]  Y. Chapuis,et al.  Endoscopic Ultrasonography for the Preoperative Localization of Insulinomas , 1996, Pancreas.

[173]  D. Metz,et al.  Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. , 1995, Gastroenterology.

[174]  P. Ruszniewski,et al.  Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. , 1995, Surgery.

[175]  B. Wiedenmann,et al.  Localisation of neuroendocrine tumours of the upper gastrointestinal tract. , 1994, Gut.

[176]  O. Luinetti,et al.  Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. , 1993, Gastroenterology.

[177]  C. Lightdale,et al.  Localization of pancreatic endocrine tumors by endoscopic ultrasonography. , 1992, The New England journal of medicine.

[178]  W. Lees,et al.  Endoscopic ultrasound for localisation of islet cell tumours. , 1992, Gut.

[179]  P. E. Smith,et al.  Orbital pseudotumour secondary to giant cell arteritis: an unreported condition. , 1990, BMJ.

[180]  U. Hellman,et al.  A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. , 1990, Acta endocrinologica.

[181]  D. O'Connor,et al.  Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. , 1989, Clinical chemistry.

[182]  L. Deftos,et al.  Hormone-negative, chromogranin A-positive endocrine tumors. , 1989, The New England journal of medicine.

[183]  P. Cisek,et al.  Catechol estrogen adducts. , 1988, Journal of steroid biochemistry.

[184]  K. Johnson An Update. , 1984, Journal of food protection.

[185]  J. Glass,et al.  Biochemical markers. , 1981, Science.

[186]  J. Galambos,et al.  Diagnosis of gastrinoma by the secretin suppression test. , 1976, Surgery, gynecology & obstetrics.

[187]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.

[188]  N. Levine THE BIOLOGICAL APPROACH , 1950 .